Oral presentation to highlight first-ever clinical evidence supporting use of a targeted GYS1 substrate reduction therapy, ABX1100, in patients with late-onset Oral presentation to highlight first-ever clinical evidence supporting use of a targeted GYS1 substrate reduction therapy, ABX1100, in patients with late-onset

Aro Biotherapeutics to Present Clinical Update from its Pompe Disease Program at the 22nd Annual WORLDSymposium

Oral presentation to highlight first-ever clinical evidence supporting use of a targeted GYS1 substrate reduction therapy, ABX1100, in patients with late-onset Pompe disease (LOPD)

PHILADELPHIA–(BUSINESS WIRE)–Aro Biotherapeutics, a clinical-stage biotechnology company developing potent and tissue-targeted short-interfering RNA (siRNA) medicines, today announced that it will present interim clinical data from its ongoing Phase 1b clinical trial of ABX1100, a novel investigational therapy for the treatment of late-onset Pompe disease (LOPD), at the 22nd annual WORLDSymposium in San Diego, Calif.

In an oral presentation at the WORLDSymposium, Ozlem Goker-Alpan, M.D., president of the Lysosomal and Rare Disorders Research and Treatment Center in Fairfax, Va., will present preliminary analyses of the safety and tolerability, as well as biomarker and pharmacodynamic activity, of ABX1100 in patients with LOPD who are currently receiving enzyme replacement therapy (ERT). The data provide the first clinical evidence of a GYS1-targeting substrate reduction therapy and its potential utility in patients with LOPD.

The presentation details are as follows:

Title: Safety, tolerability and biological activity of ABX1100, a CD71 Centyrin siRNA conjugate targeting GYS1 in Late-Onset Pompe Disease Patients

Presentation Type: Oral

Presenter: Ozlem Goker-Alpan, M.D., president, Lysosomal and Rare Disorders Research and Treatment Center

Date: Thursday, February 5, 2026 at 1:30pm PST

More information about the Phase 1b trial of ABX1100 is available at ClinicalTrials.gov, using the ID no. NCT06109948.

About ABX1100

ABX1100, an investigational treatment for Pompe disease, is comprised of a CD71 receptor-binding Centyrin conjugated to a short-interfering RNA (siRNA) that specifically interferes with expression of GYS1 messenger RNA (mRNA), thereby reducing levels and overall activity of GYS1, the enzyme responsible for glycogen production, in muscle tissues. ABX1100 has received Orphan Drug Designation and Rare Pediatric Disease status from the United States Food and Drug Administration.

About Pompe Disease

Pompe disease is a rare neuromuscular disorder caused by a genetic deficiency of the acid alpha-glucosidase (GAA), which leads to a toxic buildup of glycogen in the muscle. This buildup leads to progressive loss of muscle function, weakness, and disability that can eventually progress to death from respiratory failure. Late-onset Pompe disease (LOPD) is a subtype of Pompe that has onset after the first year of life. The current standard of care for LOPD is enzyme replacement therapy (ERT), which aims to restore genetically deficient enzymes. Despite the availability of ERT, significant unmet need remains due to limited ERT efficacy and burden of care. ERT requires intravenous infusions that can last as long as 6 hours, multiple times a month.

About Aro Biotherapeutics

Aro Biotherapeutics is a biotechnology company working to develop potent and versatile tissue-targeted short-interfering RNA (siRNA) medicines for the treatment of immune-mediated diseases and diseases with high unmet medical need. The company is developing a wholly owned pipeline of therapeutic candidates for a diverse set of diseases, employing a proprietary protein technology called Centyrins, which are small proteins engineered for exceptional efficiency, versatility, and safety. For more information, visit https://www.AroBiotx.com/.

Contacts

SmithSolve

Elan Schnitzer

973-886-9150

[email protected]

Market Opportunity
Everscale Logo
Everscale Price(EVER)
$0.00943
$0.00943$0.00943
-3.38%
USD
Everscale (EVER) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Microsoft Corp. $MSFT blue box area offers a buying opportunity

Microsoft Corp. $MSFT blue box area offers a buying opportunity

The post Microsoft Corp. $MSFT blue box area offers a buying opportunity appeared on BitcoinEthereumNews.com. In today’s article, we’ll examine the recent performance of Microsoft Corp. ($MSFT) through the lens of Elliott Wave Theory. We’ll review how the rally from the April 07, 2025 low unfolded as a 5-wave impulse followed by a 3-swing correction (ABC) and discuss our forecast for the next move. Let’s dive into the structure and expectations for this stock. Five wave impulse structure + ABC + WXY correction $MSFT 8H Elliott Wave chart 9.04.2025 In the 8-hour Elliott Wave count from Sep 04, 2025, we saw that $MSFT completed a 5-wave impulsive cycle at red III. As expected, this initial wave prompted a pullback. We anticipated this pullback to unfold in 3 swings and find buyers in the equal legs area between $497.02 and $471.06 This setup aligns with a typical Elliott Wave correction pattern (ABC), in which the market pauses briefly before resuming its primary trend. $MSFT 8H Elliott Wave chart 7.14.2025 The update, 10 days later, shows the stock finding support from the equal legs area as predicted allowing traders to get risk free. The stock is expected to bounce towards 525 – 532 before deciding if the bounce is a connector or the next leg higher. A break into new ATHs will confirm the latter and can see it trade higher towards 570 – 593 area. Until then, traders should get risk free and protect their capital in case of a WXY double correction. Conclusion In conclusion, our Elliott Wave analysis of Microsoft Corp. ($MSFT) suggested that it remains supported against April 07, 2025 lows and bounce from the blue box area. In the meantime, keep an eye out for any corrective pullbacks that may offer entry opportunities. By applying Elliott Wave Theory, traders can better anticipate the structure of upcoming moves and enhance risk management in volatile markets. Source: https://www.fxstreet.com/news/microsoft-corp-msft-blue-box-area-offers-a-buying-opportunity-202509171323
Share
BitcoinEthereumNews2025/09/18 03:50
WTI drifts higher above $59.50 on Kazakh supply disruptions

WTI drifts higher above $59.50 on Kazakh supply disruptions

The post WTI drifts higher above $59.50 on Kazakh supply disruptions appeared on BitcoinEthereumNews.com. West Texas Intermediate (WTI), the US crude oil benchmark
Share
BitcoinEthereumNews2026/01/21 11:24
MYX Finance price surges again as funding rate points to a crash

MYX Finance price surges again as funding rate points to a crash

MYX Finance price went parabolic again as the recent short-squeeze resumed. However, the formation of a double-top pattern and the funding rate point to an eventual crash in the coming days. MYX Finance (MYX) came in the spotlight earlier this…
Share
Crypto.news2025/09/18 02:57